Eslicarbazepine acetate

Eslicarbazepine acetate

Eslicarbazepine acetate
Systematic (IUPAC) name
(S)-10-Acetoxy- 10,11-dihydro- 5H-dibenz[b,f]azepine- 5-carboxamide
Clinical data
Pregnancy cat.
  • C
Legal status
Routes Oral
Pharmacokinetic data
Excretion ~90% renal
Identifiers
CAS number
ATC code N03
PubChem
ChemSpider
ChEMBL  YesY
Chemical data
Formula C17H16N2O3 
Mol. mass 296.320 g/mol

Eslicarbazepine acetate (brand names Aptiom, Zebinix, Exalief), abbreviated as ESL, is an anticonvulsant approved for use in Europe and the United States as an adjunctive therapy for epilepsy.

Similarly to oxcarbazepine, ESL behaves as a prodrug to eslicarbazepine ((S)-(+)-licarbazepine).[1] As such, their mechanisms of action are identical.[2] However, there may be pharmacokinetic differences between the two drugs; for instance, ESL may not produce as high of peak levels of (S)-(+)-licarbazepine immediately after dosing as does oxcarbazepine, which could, in theory, improve tolerability.

Like oxcarbazepine, ESL may be used to treat bipolar disorder and trigeminal neuralgia.

See also

References

  1. ^ Rogawski MA (June 2006). "Diverse mechanisms of antiepileptic drugs in the development pipeline". Epilepsy Res. 69 (3): 273–94.  
  2. ^ Rogawski MA, Löscher W (July 2004). "The neurobiology of antiepileptic drugs". Nat. Rev. Neurosci. 5 (7): 553–64.